{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,6,11]],"date-time":"2026-06-11T00:13:48Z","timestamp":1781136828748,"version":"3.54.1"},"reference-count":20,"publisher":"Oxford University Press (OUP)","issue":"D1","license":[{"start":{"date-parts":[[2020,10,17]],"date-time":"2020-10-17T00:00:00Z","timestamp":1602892800000},"content-version":"vor","delay-in-days":0,"URL":"http:\/\/creativecommons.org\/licenses\/by\/4.0\/"}],"funder":[{"DOI":"10.13039\/100010269","name":"Wellcome Trust","doi-asserted-by":"publisher","award":["206194"],"award-info":[{"award-number":["206194"]}],"id":[{"id":"10.13039\/100010269","id-type":"DOI","asserted-by":"publisher"}]},{"name":"Open Targets","award":["OTAR2-055"],"award-info":[{"award-number":["OTAR2-055"]}]},{"name":"Open Targets","award":["OTAR015"],"award-info":[{"award-number":["OTAR015"]}]}],"content-domain":{"domain":[],"crossmark-restriction":false},"short-container-title":[],"published-print":{"date-parts":[[2021,1,8]]},"abstract":"<jats:title>Abstract<\/jats:title><jats:p>CRISPR genetic screens in cancer cell models are a powerful tool to elucidate oncogenic mechanisms and to identify promising therapeutic targets. The Project Score database (https:\/\/score.depmap.sanger.ac.uk\/) uses genome-wide CRISPR\u2013Cas9 dropout screening data in hundreds of highly annotated cancer cell models to identify genes required for cell fitness and prioritize novel oncology targets. The Project Score database currently allows users to investigate the fitness effect of 18 009 genes tested across 323 cancer cell models. Through interactive interfaces, users can investigate data by selecting a specific gene, cancer cell model or tissue type, as well as browsing all gene fitness scores. Additionally, users can identify and rank candidate drug targets based on an established oncology target prioritization pipeline, incorporating genetic biomarkers and clinical datasets for each target, and including suitability for drug development based on pharmaceutical tractability. Data are freely available and downloadable. To enhance analyses, links to other key resources including Open Targets, COSMIC, the Cell Model Passports, UniProt and the Genomics of Drug Sensitivity in Cancer are provided. The Project Score database is a valuable new tool for investigating genetic dependencies in cancer cells and the identification of candidate oncology targets.<\/jats:p>","DOI":"10.1093\/nar\/gkaa882","type":"journal-article","created":{"date-parts":[[2020,10,14]],"date-time":"2020-10-14T12:14:16Z","timestamp":1602677656000},"page":"D1365-D1372","source":"Crossref","is-referenced-by-count":92,"title":["Project Score database: a resource for investigating cancer cell dependencies and prioritizing therapeutic targets"],"prefix":"10.1093","volume":"49","author":[{"given":"Lisa","family":"Dwane","sequence":"first","affiliation":[{"name":"Wellcome Sanger Institute, Hinxton, Cambridge CB10 1SA, UK"},{"name":"Open Targets, Wellcome Genome Campus, Hinxton, Cambridge CB10 1SD, UK"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Fiona M","family":"Behan","sequence":"additional","affiliation":[{"name":"Wellcome Sanger Institute, Hinxton, Cambridge CB10 1SA, UK"},{"name":"Open Targets, Wellcome Genome Campus, Hinxton, Cambridge CB10 1SD, UK"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Emanuel","family":"Gon\u00e7alves","sequence":"additional","affiliation":[{"name":"Wellcome Sanger Institute, Hinxton, Cambridge CB10 1SA, UK"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Howard","family":"Lightfoot","sequence":"additional","affiliation":[{"name":"Wellcome Sanger Institute, Hinxton, Cambridge CB10 1SA, UK"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Wanjuan","family":"Yang","sequence":"additional","affiliation":[{"name":"Wellcome Sanger Institute, Hinxton, Cambridge CB10 1SA, UK"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Dieudonne","family":"van\u00a0der\u00a0Meer","sequence":"additional","affiliation":[{"name":"Wellcome Sanger Institute, Hinxton, Cambridge CB10 1SA, UK"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Rebecca","family":"Shepherd","sequence":"additional","affiliation":[{"name":"Wellcome Sanger Institute, Hinxton, Cambridge CB10 1SA, UK"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Miguel","family":"Pignatelli","sequence":"additional","affiliation":[{"name":"Wellcome Sanger Institute, Hinxton, Cambridge CB10 1SA, UK"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Francesco","family":"Iorio","sequence":"additional","affiliation":[{"name":"Wellcome Sanger Institute, Hinxton, Cambridge CB10 1SA, UK"},{"name":"Open Targets, Wellcome Genome Campus, Hinxton, Cambridge CB10 1SD, UK"},{"name":"Human Technopole, 20157 Milano, Italy"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-2618-4237","authenticated-orcid":false,"given":"Mathew J","family":"Garnett","sequence":"additional","affiliation":[{"name":"Wellcome Sanger Institute, Hinxton, Cambridge CB10 1SA, UK"},{"name":"Open Targets, Wellcome Genome Campus, Hinxton, Cambridge CB10 1SD, UK"}],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"286","published-online":{"date-parts":[[2020,10,17]]},"reference":[{"key":"2021010313125219200_B1","doi-asserted-by":"crossref","first-page":"38","DOI":"10.1186\/1756-8722-6-38","article-title":"Targeted therapy for HER2 positive breast cancer","volume":"6","author":"Incorvati","year":"2013","journal-title":"J. Hematol. Oncol."},{"key":"2021010313125219200_B2","doi-asserted-by":"crossref","first-page":"2507","DOI":"10.1056\/NEJMoa1103782","article-title":"Improved survival with vemurafenib in melanoma with BRAF V600E mutation","volume":"364","author":"Chapman","year":"2011","journal-title":"N. Engl. J. Med."},{"key":"2021010313125219200_B3","doi-asserted-by":"crossref","first-page":"2040","DOI":"10.1056\/NEJMoa071834","article-title":"Cetuximab for the treatment of colorectal cancer","volume":"357","author":"Jonker","year":"2007","journal-title":"N. Engl. J. Med."},{"key":"2021010313125219200_B4","doi-asserted-by":"crossref","first-page":"569","DOI":"10.1038\/nrd4090","article-title":"Trial watch: phase II and phase III attrition rates 2011\u20132012","volume":"12","author":"Arrowsmith","year":"2013","journal-title":"Nat. Rev. Drug Discov."},{"key":"2021010313125219200_B5","doi-asserted-by":"crossref","first-page":"20","DOI":"10.1016\/j.jhealeco.2016.01.012","article-title":"Innovation in the pharmaceutical industry: new estimates of R&D costs","volume":"47","author":"DiMasi","year":"2016","journal-title":"J. Health Econ."},{"key":"2021010313125219200_B6","doi-asserted-by":"crossref","first-page":"1037","DOI":"10.1016\/j.drudis.2011.09.007","article-title":"What makes a good drug target?","volume":"16","author":"Gashaw","year":"2011","journal-title":"Drug Discov. Today"},{"key":"2021010313125219200_B7","doi-asserted-by":"crossref","first-page":"856","DOI":"10.1038\/ng.3314","article-title":"The support of human genetic evidence for approved drug indications","volume":"47","author":"Nelson","year":"2015","journal-title":"Nat. Genet."},{"key":"2021010313125219200_B8","doi-asserted-by":"crossref","first-page":"e1008489","DOI":"10.1371\/journal.pgen.1008489","article-title":"Are drug targets with genetic support twice as likely to be approved? Revised estimates of the impact of genetic support for drug mechanisms on the probability of drug approval","volume":"15","author":"King","year":"2019","journal-title":"PLoS Genet."},{"key":"2021010313125219200_B9","doi-asserted-by":"crossref","first-page":"511","DOI":"10.1038\/s41586-019-1103-9","article-title":"Prioritization of cancer therapeutic targets using CRISPR\u2013Cas9 screens","volume":"568","author":"Behan","year":"2019","journal-title":"Nature"},{"key":"2021010313125219200_B10","doi-asserted-by":"crossref","first-page":"551","DOI":"10.1038\/s41586-019-1102-x","article-title":"WRN helicase is a synthetic lethal target in microsatellite unstable cancers","volume":"568","author":"Chan","year":"2019","journal-title":"Nature"},{"key":"2021010313125219200_B11","doi-asserted-by":"crossref","first-page":"D985","DOI":"10.1093\/nar\/gkw1055","article-title":"Open Targets: a platform for therapeutic target identification and validation","volume":"45","author":"Koscielny","year":"2017","journal-title":"Nucleic Acids Res."},{"key":"2021010313125219200_B12","doi-asserted-by":"crossref","first-page":"D923","DOI":"10.1093\/nar\/gky872","article-title":"Cell Model Passports: a hub for clinical, genetic and functional datasets of preclinical cancer models","volume":"47","author":"van\u00a0der\u00a0Meer","year":"2019","journal-title":"Nucleic Acids Res."},{"key":"2021010313125219200_B13","doi-asserted-by":"crossref","first-page":"D955","DOI":"10.1093\/nar\/gks1111","article-title":"Genomics of Drug Sensitivity in Cancer (GDSC): a resource for therapeutic biomarker discovery in cancer cells","volume":"41","author":"Yang","year":"2013","journal-title":"Nucleic Acids Res."},{"key":"2021010313125219200_B14","doi-asserted-by":"crossref","first-page":"604","DOI":"10.1186\/s12864-018-4989-y","article-title":"Unsupervised correction of gene-independent cell responses to CRISPR\u2013Cas9 targeting","volume":"19","author":"Iorio","year":"2018","journal-title":"BMC Genomics"},{"key":"2021010313125219200_B15","doi-asserted-by":"crossref","first-page":"164","DOI":"10.1186\/s12859-016-1015-8","article-title":"BAGEL: a computational framework for identifying essential genes from pooled library screens","volume":"17","author":"Hart","year":"2016","journal-title":"BMC Bioinformatics"},{"key":"2021010313125219200_B16","doi-asserted-by":"crossref","first-page":"554","DOI":"10.1186\/s13059-014-0554-4","article-title":"MAGeCK enables robust identification of essential genes from genome-scale CRISPR\/Cas9 knockout screens","volume":"15","author":"Li","year":"2014","journal-title":"Genome Biol."},{"key":"2021010313125219200_B17","doi-asserted-by":"crossref","first-page":"D679","DOI":"10.1093\/nar\/gkw997","article-title":"GenomeCRISPR: a database for high-throughput CRISPR\/Cas9 screens","volume":"45","author":"Rauscher","year":"2017","journal-title":"Nucleic Acids Res."},{"key":"2021010313125219200_B18","doi-asserted-by":"crossref","first-page":"D776","DOI":"10.1093\/nar\/gkx993","article-title":"PICKLES: the database of pooled in-vitro CRISPR knockout library essentiality screens","volume":"46","author":"Lenoir","year":"2018","journal-title":"Nucleic Acids Res."},{"key":"2021010313125219200_B19","doi-asserted-by":"crossref","first-page":"5817","DOI":"10.1038\/s41467-019-13805-y","article-title":"Agreement between two large pan-cancer CRISPR\u2013Cas9 gene dependency data sets","volume":"10","author":"Dempster","year":"2019","journal-title":"Nat. Commun."},{"key":"2021010313125219200_B20","doi-asserted-by":"crossref","DOI":"10.1101\/2020.05.22.110247","article-title":"Integrated cross-study datasets of genetic dependencies in cancer","author":"Pacini","year":"2020"}],"container-title":["Nucleic Acids Research"],"original-title":[],"language":"en","link":[{"URL":"http:\/\/academic.oup.com\/nar\/article-pdf\/49\/D1\/D1365\/35364248\/gkaa882.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"syndication"},{"URL":"http:\/\/academic.oup.com\/nar\/article-pdf\/49\/D1\/D1365\/35364248\/gkaa882.pdf","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2021,4,8]],"date-time":"2021-04-08T18:51:55Z","timestamp":1617907915000},"score":1,"resource":{"primary":{"URL":"https:\/\/academic.oup.com\/nar\/article\/49\/D1\/D1365\/5929235"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2020,10,17]]},"references-count":20,"journal-issue":{"issue":"D1","published-online":{"date-parts":[[2020,10,17]]},"published-print":{"date-parts":[[2021,1,8]]}},"URL":"https:\/\/doi.org\/10.1093\/nar\/gkaa882","relation":{},"ISSN":["0305-1048","1362-4962"],"issn-type":[{"value":"0305-1048","type":"print"},{"value":"1362-4962","type":"electronic"}],"subject":[],"published-other":{"date-parts":[[2021,1,8]]},"published":{"date-parts":[[2020,10,17]]}}}